NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001756

Registered date:05/03/2009

Hepatitis B immunoglobulin plus Lamivudine to prevent recurrent hepatitis B following liver transplantation

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedLiver transplant candidates with end-stage liver diseases due to hepatitis B.
Date of first enrollment2009/02/01
Target sample size20
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Lamivudine

Outcome(s)

Primary OutcomeThe rate of hepatitis B recurrence post liver-transplantation.
Secondary OutcomeTo compare the rate of Hepatitis B recurrence post liver-transplantation to our histolical control (HBIG alone).

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1) HIV co-infection. 2) Lamivudine sensitivity. 3) Severe renal dysfunction (serum Cr >= 2.0 mg/dL) 4) Resistance to Lamivudine.

Related Information

Contact

public contact
Name Noriyo Yamashiki
Address 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 Japan
Telephone 03-3815-5411
E-mail nyamashiki-gi@umin.ac.jp
Affiliation University of Tokyo Organ Transplantation Service
scientific contact
Name Yasuhiko Sugawara
Address 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655 Japan
Telephone 03-3815-5411
E-mail
Affiliation University of Tokyo The Artificial Organ and Transplantation Division, Department of Surgery